SNDX Stock Overview
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Syndax Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.71 |
| 52 Week High | US$25.07 |
| 52 Week Low | US$12.06 |
| Beta | 0.92 |
| 1 Month Change | -16.30% |
| 3 Month Change | 4.90% |
| 1 Year Change | -38.90% |
| 3 Year Change | -20.89% |
| 5 Year Change | 29.10% |
| Change since IPO | 14.15% |
Recent News & Updates
Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?
Feb 07
Syndax Looks Tantalizing, But Looks Can Be Deceptive
Jan 22Recent updates
Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?
Feb 07Syndax Looks Tantalizing, But Looks Can Be Deceptive
Jan 22We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully
Oct 14Syndax Pharmaceuticals: Navigating Through A Pivotal Year
Sep 20Syndax: Gearing Up For Launches
Jun 21Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Jun 20Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Mar 28Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Mar 04Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?
Nov 20Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Sep 27Syndax Pharmaceuticals Q2 2022 Earnings Preview
Aug 07Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
Apr 08Shareholder Returns
| SNDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.1% | -2.4% | -0.2% |
| 1Y | -38.9% | -6.8% | 8.1% |
Return vs Industry: SNDX underperformed the US Biotechs industry which returned -6.8% over the past year.
Return vs Market: SNDX underperformed the US Market which returned 8.1% over the past year.
Price Volatility
| SNDX volatility | |
|---|---|
| SNDX Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SNDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SNDX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 270 | Michael Metzger | www.syndax.com |
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are Revuforj, a menin inhibitor, which has completed phase 2 clinical trial for the treatment of relapsed or refractory and acute leukemia. The company is revumenib for R/R mNPM1 AML and studying the use of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia across the treatment landscape, including in newly diagnosed patients.
Syndax Pharmaceuticals, Inc. Fundamentals Summary
| SNDX fundamental statistics | |
|---|---|
| Market cap | US$1.18b |
| Earnings (TTM) | -US$318.76m |
| Revenue (TTM) | US$23.68m |
49.8x
P/S Ratio-3.7x
P/E RatioIs SNDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNDX income statement (TTM) | |
|---|---|
| Revenue | US$23.68m |
| Cost of Revenue | US$242.47m |
| Gross Profit | -US$218.79m |
| Other Expenses | US$99.97m |
| Earnings | -US$318.76m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.71 |
| Gross Margin | -923.96% |
| Net Profit Margin | -1,346.11% |
| Debt/Equity Ratio | 119.3% |
How did SNDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 04:35 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syndax Pharmaceuticals, Inc. is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Jason Zemansky | BofA Global Research |
| Madhu Kumar | B. Riley Securities, Inc. |